Cargando…
Predicting the future of anti-tumor necrosis factor therapy
Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonrespo...
Autor principal: | Verweij, Cornelis L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714140/ https://www.ncbi.nlm.nih.gov/pubmed/19591638 http://dx.doi.org/10.1186/ar2724 |
Ejemplares similares
-
Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015) -
Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017) -
Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014) -
Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009) -
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)